Wyeth IMS Company Profile

Summary

IMS Health's Company Profiles give you the authoritative insight into a company at a strategic and local level.

Each individual IMS Company Profile analyzes the critical components that make up a pharmaceutical company, providing you with a clear assessment of the relative strengths and weaknesses of a company's business strategy.

• Critical analyses provided by an in-house expert team
• 90+ full in-depth company profiles covering all major pharmaceutical companies worldwide
• Generic, Biotechnology and Drug Delivery companies
• Includes IMS Health sales data on products and therapies
• In depth product and R&D reviews, including clinical trial, lifecycle management, competition and analysts forecasts
• Mergers and acquisitions; licensing agreements
• Forecasts and comments from leading financial analysts
• Companies' conferences, annual reports, press releases
• Comments from stockbrokers/analysts reports used throughout the profile and especially within the Strategy, Financial and Product sections.

This report covers the following industry codes:

SIC Code: 2834

NAICS Code: 325412

Contents

• Corporate Structure
• Strategy statement
• Highlights a company's strengths / weaknesses and its potential for future growth. The strategy analysis gives you an insight into the following:
  • M&A
  • Regional strategies
  • Therapeutic focus
  • R&D strategy
  • Licensing activities
  • Commentary on future prospects, including brokers' overviews
  • Interview with a key person (where available), including quotes and opinions
  • Forecasting table (top 30 companies only), showing events with major potential impact
• Financial Review
• Company sales performance as well as analyst's comments and forecasts.
• Company Sales Performance:
  • Financial review
  • Latest results
  • Sales by geographical region & leading country
  • Sales by country and subsidiary
  • Analysis comments
• Product Portfolio
• Company Profiles reviews up to 40 products per company, whilst annual reports from the top 10 pharmaceutical companies cover up to a maximum of 10 drugs.
• The section shows:
  • Summary table of products facing patent expiry.
  • Breakdown by relevant therapy area, within which, each product is discussed under the following headings: general, licensing, patents, clinical data, lifecycle management, competition and analysts' forecasts/comments.
• R&D Pipelines
• Comprehensive details of the projects that the company has in its R&D pipeline including:
  • Research pipeline summary table.
  • Introduction to the R&D activities of the company.
  • Breakdown by relevant therapy area, within which, each project is detailed (up to 2 A4 pages), including information on clinical status and analysts' forecasts.
  • Quotes from senior personnel gleaned from conferences may also be included in this section when available.
• Key figures
  • Sales by business segment.
  • Sales by geographical region.
• Analyst figures
• IMS sales data
  • Pharmaceutical sales by geographical region and leading countries.
  • Top 5 third level therapeutic classes.
  • Leading international products
  • Pharmaceutical sales analysis by age
• Employee data
• Licensing/Co-Marketing Agreements
• Displayed in a tabular format to enable you to have t a glancereview of the licensing activities of the company.
• Three sections are available to review licensing activities:
  • Marketed products
  • R&D pipeline products
  • General research collaborations, including combinatorial chemistry, proprietary technologies etc.
• Major Events
• Summary of the major events that have affected the company. This includes recent and historical events.
• Two sections
  • Mergers and Acquisitions
  • Other major events
• Events are organised in chronological order.
• Subsidiaries listing
• Mini-profile of each subsidiary that the company has worldwide showing address, major contacts and principal products.
• Other IMS Company Profiles